These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 30784262)
1. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics. Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262 [TBL] [Abstract][Full Text] [Related]
2. Fragment-Based Drug Design of Selective HDAC6 Inhibitors. Ruzic D; Djokovic N; Nikolic K Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126 [TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
5. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969 [TBL] [Abstract][Full Text] [Related]
6. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors. Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266 [TBL] [Abstract][Full Text] [Related]
8. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis. Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786 [TBL] [Abstract][Full Text] [Related]
9. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group? Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561 [TBL] [Abstract][Full Text] [Related]
10. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs). Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease. Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020). Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465 [TBL] [Abstract][Full Text] [Related]
13. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach. Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500 [TBL] [Abstract][Full Text] [Related]
14. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies. Uba AI; Yelekçi K Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380 [TBL] [Abstract][Full Text] [Related]
15. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106 [TBL] [Abstract][Full Text] [Related]
16. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976 [TBL] [Abstract][Full Text] [Related]
17. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6. Sixto-López Y; Bello M; Correa-Basurto J J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the discovery of potent and selective HDAC6 inhibitors. Wang XX; Wan RZ; Liu ZP Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060 [TBL] [Abstract][Full Text] [Related]
19. Recent innovative advances in the discovery of selective HDAC6 inhibitors. T Tavares M; Shen S Future Med Chem; 2021 Jun; 13(12):1017-1019. PubMed ID: 33906379 [No Abstract] [Full Text] [Related]
20. An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches. Banerjee S; Jana S; Jha T; Ghosh B; Adhikari N Comput Biol Chem; 2024 Jun; 110():108051. PubMed ID: 38520883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]